Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Long-Term Deferred Tax (2016 - 2024)

Historic Long-Term Deferred Tax for Sanofi (SNY) over the last 17 years, with Q2 2025 value amounting to $9.1 billion.

  • Sanofi's Long-Term Deferred Tax rose 1556.19% to $9.1 billion in Q2 2025 from the same period last year, while for Jun 2025 it was $9.1 billion, marking a year-over-year increase of 1556.19%. This contributed to the annual value of $8.5 billion for FY2024, which is 2245.76% up from last year.
  • Per Sanofi's latest filing, its Long-Term Deferred Tax stood at $9.1 billion for Q2 2025, which was up 1556.19% from $8.5 billion recorded in Q4 2024.
  • In the past 5 years, Sanofi's Long-Term Deferred Tax registered a high of $9.1 billion during Q2 2025, and its lowest value of $5.1 billion during Q2 2021.
  • Moreover, its 5-year median value for Long-Term Deferred Tax was $6.5 billion (2023), whereas its average is $6.6 billion.
  • In the last 5 years, Sanofi's Long-Term Deferred Tax crashed by 402.14% in 2021 and then soared by 2724.25% in 2023.
  • Quarter analysis of 5 years shows Sanofi's Long-Term Deferred Tax stood at $5.3 billion in 2021, then grew by 4.37% to $5.5 billion in 2022, then grew by 25.96% to $6.9 billion in 2023, then grew by 23.12% to $8.5 billion in 2024, then increased by 6.47% to $9.1 billion in 2025.
  • Its Long-Term Deferred Tax was $9.1 billion in Q2 2025, compared to $8.5 billion in Q4 2024 and $7.8 billion in Q2 2024.